No abstract

Multispectral palmprint recognition has shown broad prospects for personal identification due to its high accuracy and great stability. In this paper, we develop a novel illumination-invariant multispectral palmprint recognition method. To combine the information from multiple spectral bands, an image-level fusion framework is completed based on a fast and adaptive bidimensional empirical mode decomposition (FABEMD) and a weighted Fisher criterion. The FABEMD technique decomposes the multispectral images into their bidimensional intrinsic mode functions (BIMFs), on which an illumination compensation operation is performed. The weighted Fisher criterion is to construct the fusion coefficients at the decomposition level, making the images be separated correctly in the fusion space. The image fusion framework has shown strong robustness against illumination variation. In addition, a tensor-based extreme learning machine (TELM) mechanism is presented for feature extraction and classification of two-dimensional (2D) images. In general, this method has fast learning speed and satisfying recognition accuracy. Comprehensive experiments conducted on the PolyU multispectral palmprint database illustrate that the proposed method can achieve favorable results. For the testing under ideal illumination, the recognition accuracy is as high as 99.93%, and the result is 99.50% when the lighting condition is unsatisfied.

No abstract

Background To evaluate the value of locoregional radiation therapy (LRRT) in de novo metastatic nasopharyngeal carcinoma (mNPC) and identify suitable candidates for additional LRRT after palliative chemotherapy (PCT). Methods Patients with de novo mNPC received platinum‐based chemotherapy for a minimum of four cycles with or without definitive LRRT via intensity‐modulated radiation therapy (IMRT) were all candidates for this study. Results A total of 168 patients were included for this analysis. Additional LRRT was associated with significantly longer median OS (69.5 vs. 17.8 months, p < 0.001) when compared with PCT alone. However, this survival benefit of LRRT was only reflected in patients with oligometastatic diseases (90.8 vs. 17 months, p < 0.001), but not for those with polymetastatic disease (p = 0.86). Conclusions Additional LRRT after PCT may only improve OS for oligometastatic patients. For patients with polymetastatic disease, intensive systemic treatment such as the combination of immunotherapy and adequate PCT might be necessary.